Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Description

All subjects will receive the vaccine subcutaneously every 3 weeks x 3 with optional yearly booster vaccines up to and including 5 years post last vaccine for those patients who are confirmed responders to the vaccine . The rationale for using Poly-ICLC as an adjuvant are two ongoing trials at University of Pittsburgh Cancer Institute (UPCI) of the MUC1 100mer peptide vaccine - one as a therapeutic vaccine in subjects with metastatic castrate resistant prostate cancer and the other in subjects with advanced colonic adenomas at risk for developing colon cancer. The same formulation, MUC1 100mer peptide admixed with Poly-ICLC, is used in both trials. There has been no toxicity observed and the vaccine is highly immunogenic in early disease. In the proposed NSCLC trial the anti-MUC1 immune response will be thoroughly characterized.

Conditions

Non-small Cell Lung Cancer (NSCLC)

Talk to us

Study Overview

On this page

Study Details

Study overview

All subjects will receive the vaccine subcutaneously every 3 weeks x 3 with optional yearly booster vaccines up to and including 5 years post last vaccine for those patients who are confirmed responders to the vaccine . The rationale for using Poly-ICLC as an adjuvant are two ongoing trials at University of Pittsburgh Cancer Institute (UPCI) of the MUC1 100mer peptide vaccine - one as a therapeutic vaccine in subjects with metastatic castrate resistant prostate cancer and the other in subjects with advanced colonic adenomas at risk for developing colon cancer. The same formulation, MUC1 100mer peptide admixed with Poly-ICLC, is used in both trials. There has been no toxicity observed and the vaccine is highly immunogenic in early disease. In the proposed NSCLC trial the anti-MUC1 immune response will be thoroughly characterized.

Study of the Immunogenicity of the MUC1 Peptide - Poly-ICLC (polyinosinic-polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose) or HILTONOL™ Adjuvant Vaccine in Patients with Localized and Locally Advanced Non-Small Cell Lung Cancer

Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Condition
Non-small Cell Lung Cancer (NSCLC)
Intervention / Treatment

-

Contacts and Locations

Pittsburgh

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States, 15232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subjects must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) or neuroendocrine carcinoid tumor
  • * All subjects must have one of the following stages: Stage IA(T1NO); IB (T2NO), II \& IIIA (N2 negative); IIIA (N2+), IIIB (N3+)
  • * Patients must have stable disease at the time of enrollment
  • * Women and men at least 18 years of age
  • * ECOG performance status 0-1(Appendix A)
  • * Subjects must be within 4 to 24 weeks of standard of care treatment for their particular stage of disease
  • * Subjects must have acceptable organ and marrow function as defined below:
  • * Leukocytes \> 3,000/µL
  • * Absolute Neutrophils \> 1,500/µL
  • * Hemoglobin \> 10 g/dL
  • * Platelets \> 100,000/µL
  • * Total Bilirubin within normal institutional limits
  • * Creatinine within normal institutional limits OR
  • * Creatinine clearance \> 60 mL/min/1.73 m2 for subjects with above normal AST and ALT with alkaline phosphatase within \< 1.5 times upper limit of normal
  • * The effects of a MUC1vaccine on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, men and women of childbearing potential must be willing to use effective contraception (hormonal barrier method of birth control; abstinence) while on study treatment and for at least 3 months thereafter. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
  • * Subjects may not be receiving any other investigational agents
  • * Any positive ANA titer above 1:160, even in an asymptomatic individual. Note:
  • * Known Hepatitis B on immunomodulators (i.e. interferon)
  • * Known Hepatitis C on immunomodulators (i.e. interferon)
  • * No prior vaccine therapy
  • * Patients may not be receiving any steroids or other anti-immune therapy at the time of registration.
  • * Subjects must not be more than 24 weeks from standard of care treatment for their particular stage of disease
  • * Subjects must not have post-obstructive pneumonia or other serious infection at the time of registration or other serious underlying medical condition that would impair the ability of the subjects to receive protocol treatment
  • * Prior resection of lung cancer is allowed, if at least five years have elapsed between previous resection and registration
  • * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • * Pregnant women are excluded from this study. Women of childbearing potential must have a negative pregnancy test
  • * Subjects with immune deficiency are not expected to respond to the vaccine. Therefore, known HIV-positive patients are excluded from the study
  • * Subjects with a history of known autoimmune disease are excluded from this study

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Olivera Finn,

Arjun Pennathur, MD, PRINCIPAL_INVESTIGATOR, University of Pittsburgh Medical Center

Study Record Dates

2031-10